

We are funding
projects to validate
novel targets in
neurodegeneration

abbvie



astex
pharmaceuticals



lifeArc

Lilly



DEMENTIA
Consortium

dementiaconsortium.org

We are a global initiative that funds collaborative projects to validate novel therapeutic targets in neurodegenerative diseases

Funding

We are an alliance of medical research charities and pharmaceutical companies established to help advance new treatments for dementia from academic research.

The members are funding projects to support research in this area, and can provide unparalleled expertise in collaborative early stage drug discovery. Through the commercial partners, promising projects can be progressed towards the clinic, and revenues from future drugs are shared with the originating scientists.

What are we looking for?

You are an academic researcher or SME with a promising novel target for dementia that is suitable for therapy with a small molecule or antibody approach and are looking for assistance with further preclinical validation.

Disease Focus

We fund collaborative research to validate novel targets and treatments for dementia including Alzheimer's disease, dementia with Lewy bodies, tauopathies, vascular dementia, frontotemporal dementia and neurodegeneration-associated cognitive deficits, plus Parkinson's disease, amyotrophic lateral sclerosis (ALS) and Huntingdon's disease.

We support studies aimed to generate tool compounds or antibodies for preclinical target validation, providing confidence in the relevance of a target to disease.

Your research will provide evidence that a novel molecular target is associated with a neurodegenerative disease and that target modulation could be either disease modifying or cognition enhancing.

Collaboration

The research projects we support are collaborative, with participation from the consortium members throughout the project planning and prosecution.

Applicants will work with the expert high-throughput screening, medicinal chemistry and antibody engineering teams within the consortium to progress validated targets towards early drug discovery. The industrial partners may provide additional resources for projects.

Applications are assessed every 2 months. For more information and an application form please visit our website or contact us at: **info@dementiaconsortium.org**

To apply, visit dementiaconsortium.org

